| scholarly article | Q13442814 |
| P2093 | author name string | William M Baldwin | |
| Kazunori Murata | |||
| P2860 | cites work | CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens | Q24307492 |
| C5a-induced expression of P-selectin in endothelial cells | Q24633672 | ||
| Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19 | Q24676040 | ||
| Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation | Q27655398 | ||
| The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules | Q28188397 | ||
| Structure of C3b in complex with CRIg gives insights into regulation of complement activation | Q28269302 | ||
| C3d of complement as a molecular adjuvant: bridging innate and acquired immunity | Q28272810 | ||
| The chemotactic receptor for human C5a anaphylatoxin | Q28280054 | ||
| Polymorphonuclear leukocyte chemotactic activity in rabbit serum and Guinea pig serum treated with immune complexes: evidence for c5a as the major chemotactic factor | Q28303590 | ||
| Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin | Q28512587 | ||
| C5L2, a nonsignaling C5A binding protein | Q28565469 | ||
| Expression and function of the C5a receptor in rat alveolar epithelial cells | Q28572008 | ||
| VSIG4, a B7 family-related protein, is a negative regulator of T cell activation | Q28584882 | ||
| Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries | Q31961631 | ||
| Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions | Q33195220 | ||
| Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice | Q33616556 | ||
| Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation | Q71372243 | ||
| The humoral immune response towards HLA class II determinants in renal transplantation | Q71769742 | ||
| Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein | Q71803052 | ||
| Secretory vesicles are the intracellular reservoir of complement receptor 1 in human neutrophils | Q72037724 | ||
| Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps | Q72108801 | ||
| Capillary deposition of C4d complement fragment and early renal graft loss | Q72791721 | ||
| C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited | Q73326011 | ||
| Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells | Q73449844 | ||
| The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells | Q73509925 | ||
| Platelets and capillary injury in acute humoral rejection of renal allografts | Q73577045 | ||
| C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion | Q73605659 | ||
| Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1 | Q73740405 | ||
| Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice | Q73823424 | ||
| The allogeneic T and B cell response is strongly dependent on complement components C3 and C4 | Q74623666 | ||
| Complementary adhesion molecules promote neutrophil-Kupffer cell interaction and the elimination of bacteria taken up by the liver | Q77373935 | ||
| Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets | Q77841687 | ||
| The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells | Q78109868 | ||
| Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection | Q78346854 | ||
| Expression and function of C5a receptor in mouse microvascular endothelial cells | Q78489084 | ||
| Evidence That Humoral Allograft Rejection in Lung Transplant Patients Is Not Histocompatibility Antigen-Related | Q79083547 | ||
| Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo | Q79369849 | ||
| The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion | Q79370206 | ||
| The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries | Q79731732 | ||
| Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannose-binding lectin | Q79929623 | ||
| C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings | Q80061434 | ||
| C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: Implications for the destabilization of atherosclerotic plaque | Q80389242 | ||
| In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody | Q80763569 | ||
| Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants | Q81294427 | ||
| Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation | Q81317216 | ||
| C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody | Q81348933 | ||
| Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts | Q81379186 | ||
| Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine | Q81725513 | ||
| Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype | Q82732283 | ||
| Competitive binding of pentraxins and IgM to newly exposed epitopes on late apoptotic cells | Q83212241 | ||
| Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity | Q34116148 | ||
| Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers | Q34342506 | ||
| The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria | Q34567835 | ||
| Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella | Q34580848 | ||
| Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection | Q34728157 | ||
| C5a-induced gene expression in human umbilical vein endothelial cells | Q35094695 | ||
| Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity | Q35142594 | ||
| Poly's plea: membership to the club of APCs | Q35216389 | ||
| Prevention of neutrophil migration ameliorates rat lung allograft rejection | Q35586910 | ||
| Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. | Q35742666 | ||
| Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis | Q35748046 | ||
| Antibody-mediated organ-allograft rejection | Q36263023 | ||
| Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection | Q36317528 | ||
| Human platelet activation by C3a and C3a des-arg | Q36348940 | ||
| Transient perturbation of endothelial integrity induced by natural antibodies and complement | Q36364261 | ||
| Complement-mediated regulation of tissue factor activity in endothelium | Q36365648 | ||
| Decay-accelerating factor modulates induction of T cell immunity | Q36403001 | ||
| Platelet activation leads to activation and propagation of the complement system | Q36403387 | ||
| Antibody-mediated rejection in renal allografts: lessons from pathology | Q36910391 | ||
| Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production | Q37106187 | ||
| Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. | Q37371806 | ||
| Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2 | Q37652278 | ||
| Bronchiolitis obliterans syndrome after (heart-)lung transplantation. Impaired antiprotease defense and increased oxidant activity | Q38318672 | ||
| Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. | Q38352031 | ||
| Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial | Q38400764 | ||
| The involvement of FcR mechanisms in antibody-mediated rejection | Q40042379 | ||
| Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage | Q40152525 | ||
| Z39Ig is expressed on macrophages and may mediate inflammatory reactions in arthritis and atherosclerosis | Q40249030 | ||
| Flow cytometry based detection of HLA alloantibody mediated classical complement activation. | Q40597066 | ||
| The relationship of the chemotactic behavior of the complement-derived factors, C3a, C5a, and C567, and a bacterial chemotactic factor to their ability to activate the proesterase 1 of rabbit polymorphonuclear leukocytes | Q41514223 | ||
| The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions | Q41782927 | ||
| Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody | Q41816592 | ||
| Immunocomplexes stimulate different signalling events to chemoattractants in the neutrophil and regulate L-selectin and beta 2-integrin expression differently | Q41893385 | ||
| Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation | Q42482700 | ||
| Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. | Q42488331 | ||
| The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells | Q42804319 | ||
| Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial | Q43777913 | ||
| Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. | Q43931517 | ||
| Altered neutrophil trafficking during sepsis | Q44037126 | ||
| Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation | Q44102024 | ||
| C4d staining of pulmonary allograft biopsies: an immunoperoxidase study | Q44403426 | ||
| ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplantation | Q44454297 | ||
| Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial | Q44553655 | ||
| Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass | Q44781832 | ||
| C4d deposition in early renal allograft protocol biopsies | Q45022058 | ||
| Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. | Q45135071 | ||
| Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. | Q46126109 | ||
| Humoral rejection in pediatric orthotopic heart transplantation | Q46175675 | ||
| Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface | Q47172907 | ||
| Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial | Q47585646 | ||
| Significance of the positive crossmatch test in kidney transplantation | Q47800073 | ||
| Cloning of Z39Ig, a novel gene with immunoglobulin-like domains located on human chromosome X. | Q47826552 | ||
| Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
| Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome | Q47924867 | ||
| Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. | Q51696388 | ||
| C4d-positive chronic rejection: a frequent entity with a poor outcome. | Q51722871 | ||
| P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. | Q51794988 | ||
| Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. | Q51979171 | ||
| Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. | Q51990716 | ||
| C4d deposition in cardiac allografts correlates with alloantibody. | Q53267811 | ||
| Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. | Q53617258 | ||
| RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. | Q54014329 | ||
| Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. | Q54380136 | ||
| Direct binding of C1q to apoptotic cells and cell blebs induces complement activation | Q56943174 | ||
| Emergence of inflammatory alveolar macrophages during rejection or infection after lung transplantation | Q56997165 | ||
| Local synthesis of complement component C3 regulates acute renal transplant rejection | Q57369617 | ||
| Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes | Q57731391 | ||
| Incidence of C4d Stain in Protocol Biopsies from Renal Allografts: Results from a Multicenter Trial | Q58378349 | ||
| Growth control of activated, synchronized murine B cells by the C3d fragment of human complement | Q59070991 | ||
| C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a | Q59097002 | ||
| Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor | Q66971259 | ||
| Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection | Q67773387 | ||
| Activation of rat complement by soluble and insoluble rat IgA immune complexes | Q68021735 | ||
| Experiences with known ABO-mismatched renal transplants | Q68216099 | ||
| Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury | Q68642485 | ||
| The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection | Q68704052 | ||
| Interaction of immunoglobulin A with complement and phagocytic cells | Q69389397 | ||
| Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+ | Q69518480 | ||
| Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity | Q69843451 | ||
| Characterization of a receptor for C5a anaphylatoxin on human eosinophils | Q69939533 | ||
| P433 | issue | 3 | |
| P921 | main subject | antibody | Q79460 |
| pathogenesis | Q372016 | ||
| P304 | page(s) | 139-150 | |
| P577 | publication date | 2009-04-10 | |
| P1433 | published in | Transplantation Reviews | Q15749559 |
| P1476 | title | Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection | |
| P478 | volume | 23 |
| Q48241059 | Activation of Complement by Pigment Epithelium-Derived Factor in Rheumatoid Arthritis. |
| Q36302476 | An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA |
| Q34667057 | Antibodies in transplantation |
| Q33614147 | Antibody therapy can enhance AngiotensinII-induced myocardial fibrosis |
| Q35876250 | Antibody-mediated rejection: an evolving entity in heart transplantation |
| Q37414746 | Autoantibody formation in human and rat studies of chronic rejection and primary graft dysfunction |
| Q48215946 | C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients. |
| Q34901573 | Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation |
| Q47133994 | Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. |
| Q39097599 | Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis |
| Q92843908 | Combination of Glomerular C4d and Morphologic Glomerular Lesions as a Possible Indicator in the Diagnosis of Acute or Chronic Active Antibody-Mediated Rejection |
| Q34496822 | Complement activation in astrocytomas: deposition of C4d and patient outcome |
| Q84203120 | Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation |
| Q41966451 | Detection of T and B cells specific complement-fixing alloantibodies using flow cytometry: A diagnostic approach for a resource limited laboratory. |
| Q38787427 | Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation |
| Q40979777 | Early decreased plasma levels of factor B and C5a are important biomarkers in children with Kawasaki disease |
| Q92346707 | Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies |
| Q43037651 | Focal C4d staining in peritubular capillaries and kidney graft survival: results of a retrospective study |
| Q34534928 | Genotypic diversity of complement component C4 does not predict kidney transplant outcome |
| Q87599772 | Histologic evaluation of post-implantation immediate C4d deposition in 13 intestinal grafts: correlation with cell-based crossmatching, cold ischemia time, and preservation injury |
| Q49297064 | Impact of complement component 3/4/5 single nucleotide polymorphisms on renal transplant recipients with antibody-mediated rejection |
| Q64055637 | Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF |
| Q27006030 | Late and chronic antibody-mediated rejection: main barrier to long term graft survival |
| Q26997385 | Membrane attack by complement: the assembly and biology of terminal complement complexes |
| Q38196860 | Modulators of complement activation: a patent review (2008 - 2013). |
| Q37228867 | Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways |
| Q40061486 | Plasma levels of complement factor I and C4b peptides are associated with HIV suppression |
| Q33622902 | Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient |
| Q51043732 | Sequential analysis of donor-specific antibodies and pathological findings in acute antibody-mediated rejection in a rat renal transplantation model. |
| Q58081547 | Sialic acid is a critical fetal defense against maternal complement attack |
| Q53656379 | Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat. |
| Q83373484 | Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates |
| Q61449352 | Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report |
| Q27021227 | The importance of C4d in biopsies of kidney transplant recipients |
| Q52725381 | The non-haemostatic role of platelets in systemic lupus erythematosus. |
| Q26862195 | The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection |
| Q26778646 | Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage |
| Q28069336 | Unraveling the Role of Allo-Antibodies and Transplant Injury |
| Q93064481 | Utility of immunohistochemistry with C3d in C3 glomerulopathy |
Search more.